Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08LEY
|
|||
| Drug Name |
Lanadelumab
|
|||
| Synonyms |
Lanadelumab [USAN]; UNII-2372V1TKXK; 2372V1TKXK; DX-2930
Click to Show/Hide
|
|||
| Indication | Hereditary angioedema [ICD-11: 4A00.14; ICD-9: 277.6] | Approved | [1] | |
| Company |
Dyax/Shire
|
|||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Plasma kallikrein (KLKB1) | Target Info | Modulator | [1] |
| KEGG Pathway | Complement and coagulation cascades | |||
| NetPath Pathway | AndrogenReceptor Signaling Pathway | |||
| Panther Pathway | Blood coagulation | |||
| Pathwhiz Pathway | Coagulation | |||
| Reactome | Intrinsic Pathway of Fibrin Clot Formation | |||
| Activation of Matrix Metalloproteinases | ||||
| WikiPathways | Complement and Coagulation Cascades | |||
| Human Complement System | ||||
| Blood Clotting Cascade | ||||
| Formation of Fibrin Clot (Clotting Cascade) | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.